Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62388 | 0.89 | — | — | |
| SCHEMBL27798646 | 0.86 | LMNA (0.36) | LMNAALDH1A1L3MBTL1 | |
| SCHEMBL28118298 | 0.86 | LMNA (0.36) | LMNAALDH1A1L3MBTL1 | |
| Nitric Oxide SCHEMBL5490095 | 0.84 | LMNA (0.35) | LMNAALDH1A1L3MBTL1 | |
| Alcohol SCHEMBL27769789 | 0.84 | ALDH1A1 (0.37) | LMNAALDH1A1L3MBTL1 | |
| Glycerin SCHEMBL124052 | 0.83 | LMNA (0.56) | LMNAALDH1A1CA5ACA5B | |
| Glycerin SCHEMBL854170 | 0.83 | LMNA (0.56) | LMNAALDH1A1CA5ACA5B | |
| Glycerin SCHEMBL2220986 | 0.83 | LMNA (0.56) | LMNAALDH1A1CA5ACA5B | |
| Glycerin SCHEMBL7035160 | 0.83 | LMNA (0.56) | LMNAALDH1A1CA5ACA5B | |
| Glycerin SCHEMBL28512738 | 0.83 | LMNA (0.56) | LMNAALDH1A1CA5ACA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120082997-A1 | TAGGANTS AND METHOD OF USING SAME | TECHNION RESEARCH & DEVELOPMENT (IL) | 2012-04-05 | — | — | US | claimed |
| US-20120082997-A1 | TAGGANTS AND METHOD OF USING SAME | TECHNION RESEARCH & DEVELOPMENT (IL) | 2012-04-05 | — | — | US | disclosed |
| US-20040254238-A1 | Bone growth stimulation with NO/statin and other NO modulating combinations | OSTEOSCREEN (US) | 2004-12-16 | — | — | US | disclosed |
| WO-2004091626-A1 | BONE GROWTH STIMULATION WITH NO/STATIN AND OTHER NO MODULATING COMBINATIONS | OSTEOSCREEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254238-A1 | Bone growth stimulation with NO/statin and other NO modulating combinations | NOS3, NOS1, NOS2 | LMNA 4158/4885ALDH1A1 4026/4885CA5A 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.